Doximity Inc. (DOCS)
NYSE NYSE Primary 
XSTU 
Dr Martens back on its feet
It has been a tough couple of years for Dr Martens PLC (LSE:DOCS), but Berenberg thinks the bootmaker is lacing up for recovery. The broker keeps its 'buy' rating and 114p price target, saying the company's new strategy is beginning to take hold ahead of half-year results next month.
Here's Why Doximity (DOCS) Fell More Than Broader Market
In the closing of the recent trading day, Doximity (DOCS) stood at $65.61, denoting a -9.59% move from the preceding trading day.
DOCS Stock Up in Pre-Market Post Q1 Earnings Beat, Gross Margin Down
Doximity beats first-quarter fiscal 2026 estimates with double-digit revenue growth and lifts its full-year forecast.
Doximity, Inc. (DOCS) Q1 2026 Earnings Call Transcript
Doximity, Inc. (NYSE:DOCS ) Q1 2026 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Anna Bryson - Chief Financial Officer Jeffrey A. Tangney - Co-Founder, CEO & Chairperson Perry Scott Gold - Head of Investor Relations Conference Call Participants Allen Charles Lutz - BofA Securities, Research Division Brian Christopher Peterson - Raymond James & Associates, Inc., Research Division Brian Gil Tanquilut - Jefferies LLC, Research Division Craig Matthew Hettenbach - Morgan Stanley, Research Division David Michael Larsen - BTIG, LLC, Research Division Elizabeth Hammell Anderson - Evercore ISI Institutional Equities, Research Division Jessica Elizabeth Tassan - Piper Sandler & Co., Research Division Michael Aaron Cherny - Leerink Partners LLC, Research Division Ryan Michael MacDonald - Needham & Company, LLC, Research Division Ryan Scott Daniels - William Blair & Company L.L.C.
Doximity (DOCS) Q1 Earnings and Revenues Top Estimates
Doximity (DOCS) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.28 per share a year ago.
Doximity buys Pathway Medical for $63 million to help doctors get AI-powered answers
Doximity has acquired the AI startup Pathway Medical for $63 million. Pathway has one of the largest structured datasets in medicine, Doximity said.
Doximity (DOCS) Reports Next Week: Wall Street Expects Earnings Growth
Doximity (DOCS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Doximity (DOCS) Registers a Bigger Fall Than the Market: Important Facts to Note
In the latest trading session, Doximity (DOCS) closed at $59.7, marking a -2.13% move from the previous day.
Doximity: Slowing Sales And EBITDA Growth
Doximity shares have dropped nearly 25% from February highs, despite strong Q4 earnings and 17% revenue growth year-over-year. Analyst sentiment is mixed, and insider selling has notably increased in 2025. Doximity boasts a robust balance sheet with $915 million in cash, no long-term debt, and an impressive rise in free cash flow in its last reported quarter.
Doximity (DOCS) Upgraded to Strong Buy: Here's Why
Doximity (DOCS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Doximity (DOCS) Stock Drops Despite Market Gains: Important Facts to Note
In the closing of the recent trading day, Doximity (DOCS) stood at $59.38, denoting a -1.44% move from the preceding trading day.
Doximity (DOCS) Rises Higher Than Market: Key Facts
Doximity (DOCS) concluded the recent trading session at $61.55, signifying a +2.24% move from its prior day's close.
